Materna HCG 5000IU Injection contains Human Chorionic Gonadotropin (hCG) at a concentration of 5000 International Units per dose. hCG is a glycoprotein hormone produced during pregnancy, structurally similar to luteinizing hormone (LH), and is used therapeutically to stimulate ovulation and support luteal function in assisted reproductive technologies. Materna HCG 5000IU Injection is indicated for the treatment of female infertility due to anovulation, where it induces the final maturation and release of oocytes. It is also employed in male patients to stimulate testosterone production and spermatogenesis in cases of hypogonadotropic hypogonadism. The injection is administered intramuscularly or subcutaneously, with dosing individualized based on clinical response and treatment protocols. Materna HCG 5000IU Injection acts by mimicking endogenous LH, promoting follicular development and corpus luteum maintenance. Common adverse effects may include injection site reactions, headache, fatigue, and in rare cases, ovarian hyperstimulation syndrome (OHSS) in women. Caution is advised in patients with hormone-sensitive tumors or hypersensitivity to hCG. Materna HCG 5000IU Injection should be used under strict medical supervision with appropriate monitoring to optimize therapeutic outcomes and minimize risks.